Decheng Capital

Latest statistics and disclosures from Decheng Capital's latest quarterly 13F-HR filing:

Tip: Access up to 7 years of quarterly data

Positions held by Decheng Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Decheng Capital

Decheng Capital holds 14 positions in its portfolio as reported in the March 2026 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Cg Oncology (CGON) 65.2 $431M 6.4M 67.68
 View chart
Nuvation Bio (NUVB) 16.8 $111M 26M 4.29
 View chart
Upstream Bio (UPB) 3.7 $25M -13% 2.7M 9.00
 View chart
Aclaris Therapeutics (ACRS) 2.3 $15M 4.0M 3.75
 View chart
Aardvark Therapeutics (AARD) 2.2 $15M 3.9M 3.77
 View chart
Lyell Immunopharma 2.1 $14M 692k 20.06
 View chart
Newamsterdam Pharma Co Nv (NAMS) 1.6 $10M -45% 325k 32.01
 View chart
Arcus Biosciences Incorporated (RCUS) 1.6 $10M -11% 478k 21.60
 View chart
Revolution Medicines (RVMD) 1.4 $9.1M -53% 94k 97.25
 View chart
Equillium (EQ) 1.3 $8.9M 4.4M 2.00
 View chart
BeyondSpring SHS (BYSI) 0.9 $6.2M 3.8M 1.64
 View chart
Zentalis Pharmaceuticals (ZNTL) 0.5 $3.1M 1.3M 2.34
 View chart
Krystal Biotech (KRYS) 0.3 $1.9M -57% 7.3k 258.32
 View chart
Pyxis Oncology (PYXS) 0.1 $477k 327k 1.46
 View chart

Past Filings by Decheng Capital

SEC 13F filings are viewable for Decheng Capital going back to 2023